ArticleJournal of gastrointestinal oncology2026
Second-line raltitrexed plus irinotecan (SALIRI) with bevacizumab, cetuximab, or alone for metastatic colorectal cancer: a prospective multicenter cohort-based secondary analysis of the SALLY trial.
Furong Kou et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.